IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Impact of Baseline BMI on Glycemic Control and Weight Change with Metformin Monotherapy in Chinese Type 2 Diabetes Patients: Phase IV Open-Label Trial
Ji, Linong1; Li, Hongmei2; Guo, Xiaohui3; Li, Yan4; Hu, Renming5; Zhu, Zhengying6
刊名PLOS ONE
2013-02-28
DOI10.1371/journal.pone.0057222
8期:2
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Multidisciplinary Sciences
研究领域[WOS]Science & Technology - Other Topics
关键词[WOS]BODY-MASS INDEX ; NONOBESE PATIENTS ; RISK-FACTORS ; THERAPY ; HYPERGLYCEMIA ; MELLITUS ; EFFICACY ; ADULTS
英文摘要

Background: Differences exist between treatment recommendations regarding the choice of metformin as first-line therapy for type 2 diabetes patients according to body mass index (BMI). This study compared the efficacy of metformin monotherapy among normal-weight, overweight, and obese patients with newly diagnosed type 2 diabetes.

Methods: In this prospective, multicenter, open-label study in China, patients aged 23-77 years were enrolled 1: 1: 1 according to baseline BMI: normal-weight (BMI 18.5-23.9 kg/m(2); n = 125); overweight (BMI 24.0-27.9 kg/m(2); n = 122) or obese (BMI >= 28 kg/m(2); n = 124). Extended-release metformin was administered for 16 weeks (500 mg/day, up-titrated weekly to a maximum 2,000 mg/day). The primary efficacy endpoint was the effect of baseline BMI on glycemic control with metformin monotherapy, measured as the change from baseline in glycosylated hemoglobin (HbA(1c)) at week 16 compared among BMI groups using ANCOVA. Other endpoints included comparisons of metformin′s effects on fasting plasma glucose (FPG), lipid levels and body weight.

Results: Mean HbA1c decreases at week 16, adjusted for baseline values, were -1.84%, -1.78% and -1.78% in normal-weight, overweight and obese patients, (P = 0.664); body weight decreased by 2.4%, 3.9% and 3.5%, respectively. FPG levels decreased similarly over time in all BMI groups (P = 0.461) and changes from baseline in high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) did not differ significantly among BMI groups at week 16 (P = 0.143 and 0.451, respectively).

Conclusions: Baseline BMI had no impact on glycemic control, weight change or other efficacy measures with metformin monotherapy. These data suggest that normal-weight type 2 diabetes patients would derive the same benefits from first-line treatment with metformin as overweight and obese patients, and are not at increased risk of excess weight loss.

语种英语
WOS记录号WOS:000315524900060
资助机构Bristol-Myers Squibb
引用统计
被引频次:15[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/57239
专题北京大学第二临床医学院
北京大学第一临床医学院_内分泌内科
作者单位1.Peking Univ, Peoples Hosp, Dept Endocrinol & Metab, Beijing 100871, Peoples R China
2.Sino Amer Shanghai Squibb Pharmaceut Ltd, Clin Res, China Res & Dev, Shanghai, Peoples R China
3.Peking Univ, Peoples Hosp, Dept Endocrinol, Beijing 100871, Peoples R China
4.Sun Yat Sen Univ, Dept Endocrinol, Sun Yat Sen Mem Hosp, Guangzhou 510275, Guangdong, Peoples R China
5.Fudan Univ, Huashan Hosp, Dept Endocrinol & Metab, Shanghai 200433, Peoples R China
6.Bristol Myers Squibb, China Res & Dev, Clin Res, Shanghai, Peoples R China
推荐引用方式
GB/T 7714
Ji, Linong,Li, Hongmei,Guo, Xiaohui,et al. Impact of Baseline BMI on Glycemic Control and Weight Change with Metformin Monotherapy in Chinese Type 2 Diabetes Patients: Phase IV Open-Label Trial[J]. PLOS ONE,2013,8(2).
APA Ji, Linong,Li, Hongmei,Guo, Xiaohui,Li, Yan,Hu, Renming,&Zhu, Zhengying.(2013).Impact of Baseline BMI on Glycemic Control and Weight Change with Metformin Monotherapy in Chinese Type 2 Diabetes Patients: Phase IV Open-Label Trial.PLOS ONE,8(2).
MLA Ji, Linong,et al."Impact of Baseline BMI on Glycemic Control and Weight Change with Metformin Monotherapy in Chinese Type 2 Diabetes Patients: Phase IV Open-Label Trial".PLOS ONE 8.2(2013).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Ji, Linong]的文章
[Li, Hongmei]的文章
[Guo, Xiaohui]的文章
百度学术
百度学术中相似的文章
[Ji, Linong]的文章
[Li, Hongmei]的文章
[Guo, Xiaohui]的文章
必应学术
必应学术中相似的文章
[Ji, Linong]的文章
[Li, Hongmei]的文章
[Guo, Xiaohui]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。